疫情下临床试验监查的进展与知情同意:来自英国UKCRC注册临床试验单元的经验
本文总结英国UKCRC临床试验单元监查工作组在COVID-19疫情期间对临床试验监查和知情同意实践调整的经验。9个CTU的监查负责人反复讨论,识别出集中、远程和现场监查的组合最优,现场监查不可行时可用集中或集中加远程监查替代,并探讨了eConsent、最小化数据集、电子TMF和灵活培训等可行做法。
要点
- 监查宜采用集中、远程和现场监查相结合的方式。
- 现场监查不可行时,可用集中或集中加远程监查替代。
- eConsent、第三人知情同意或远程知情同意均可行。
核心结论
- COVID-19疫情迫使英国临床试验监查方式作出调整,部分做法可用于其他疫情并应纳入常规使用。
研究设计与样本
- 英国UKCRC监查任务与完成工作组由9个CTU的监查负责人组成,反复开会识别COVID-19对临床试验监查的影响。
主要发现
- 监查常以集中、远程和现场监查组合完成最佳,但现场监查不可行时仅用集中或集中加远程监查也可找到可行方案。
- eConsent、第三人知情同意或远程知情同意均可行。
- 将数据集最小化至关键数据可减少研究站点和CTU人员的工作量。
- COVID-19导致居家办公使电子试验主文件(TMF)更具吸引力。
- 允许站点在方便时预约并参加方案培训已获成功,值得在多站点试验中推广。
临床怎么用
- 在监查计划中纳入集中、远程和现场监查的组合策略。
- 现场监查受限时,优先采用集中或集中加远程监查保障患者安全与试验完整性。
- 考虑采用eConsent、第三人知情同意或远程知情同意完成知情同意。
- 将数据集最小化至关键数据以减轻站点和CTU工作量。
- 采用电子TMF并允许站点灵活预约方案培训。
局限性
- 本文为基于9个CTU监查负责人经验的学习总结,非系统性研究。
- 文中未报告样本量、定量结局或统计比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has affected how clinical trials are managed, both within existing portfolios and for the rapidly developed COVID-19 trials. Sponsors or delegated organisations responsible for monitoring trials have needed to consider and implement alternative ways of working due to the national infection risk necessitating restricted movement of staff and public, reduced clinical staff resource as research staff moved to clinical areas, and amended working arrangements for sponsor and sponsor delegates as staff moved to working from home.Organisations have often worked in isolation to fast track mitigations required for the conduct of clinical trials during the pandemic; this paper describes many of the learnings from a group of monitoring leads based in United Kingdom Clinical Research Collaboration (UKCRC) Clinical Trials Unit (CTUs) within the UK.The UKCRC Monitoring Task and Finish Group, comprising monitoring leads from 9 CTUs, met repeatedly to identify how COVID-19 had affected clinical trial monitoring. Informed consent is included as a specific issue within this paper, as review of completed consent documentation is often required within trial monitoring plans (TMPs). Monitoring is defined as involving on-site monitoring, central monitoring or/and remote monitoring.Monitoring, required to protect the safety of the patients and the integrity of the trial and ensure the protocol is followed, is often best done by a combination of central, remote and on-site monitoring. However, if on-site monitoring is not possible, workable solutions can be found using only central or central and remote monitoring. eConsent, consent by a third person, or via remote means is plausible. Minimising datasets to the critical data reduces workload for sites and CTU staff. Home working caused by COVID-19 has made electronic trial master files (TMFs) more inviting. Allowing sites to book and attend protocol training at a time convenient to them has been successful and worth pursuing for trials with many sites in the future.The arrival of COVID-19 in the UK has forced consideration of and changes to how clinical trials are conducted in relation to monitoring. Some developed practices will be useful in other pandemics and others should be incorporated into regular use.
引用
- Love SB, Armstrong E, Bayliss C, et al. Monitoring advances including consent: learning from COVID-19 trials and other trials running in UKCRC registered clinical trials units during the pandemic. Trials. 2021. PMID: 33853635. doi:10.1186/s13063-021-05225-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。